Ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab (GA101) (iFCG) for previously untreated patients with chronic lymphocytic leukemia (CLL) with mutated IGHV and non-del(17p)

被引：0
|
作者：
Jain, Nitin [1 ]
Thompson, Philip [1 ]
Burger, Jan A. [1 ]
Borthakur, Gautam [1 ]
Bose, Prithviraj [1 ]
Estrov, Zeev [1 ]
Ferrajoli, Alessandra [1 ]
Gandhi, Varsha [1 ]
Plunkett, William [1 ]
Lopez, Wanda [1 ]
Kantarjian, Hagop [1 ]
O'Brien, Susan [2 ]
Keating, Michael [1 ]
Wierda, William [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Univ Calif, Chao Family Comprehens Canc Ctr, Orange, NJ USA
[3] Univ Texas, Houston, TX USA
来源：
LEUKEMIA & LYMPHOMA | 2017年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
164
引用
收藏
页码：158 / 159
页数：2
相关论文
共 50 条
  • [41] A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with Investigator's Choice of Chemoimmunotherapy in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) without Del(17p) or TP53 Mutation
    Brown, Jennifer R.
    Eichhorst, Barbara F.
    Ghia, Paolo
    Kater, Arnon P.
    Li, Jianyong
    Khurana, Sudha
    Elhamy, Mostafa
    Wang, Min Hui
    Seymour, John F.
    BLOOD, 2019, 134
  • [42] Safety and Efficacy Of Obinutuzumab (GA101) With Fludarabine/Cyclophosphamide (G-FC) Or Bendamustine (G-B) In The Initial Therapy Of Patients With Chronic Lymphocytic Leukemia (CLL): Results From The Phase 1b Galton Trial (GA04779g)
    Brown, Jennifer R.
    O'Brien, Susan
    Kingsley, C. Daniel
    Eradat, Herbert
    Pagel, John M.
    Lymp, James
    Hirata, Jamie
    Kipps, Thomas J.
    BLOOD, 2013, 122 (21)
  • [43] Salvage Therapy with Obinutuzumab (GA101) Plus Chlorambucil (Clb) after Treatment Failure of Clb Alone in Patients with Chronic Lymphocytic Leukemia (CLL) and Comorbidities: Results of the CLL11 Study
    Goede, Valentin
    Engelke, Anja
    Fischer, Kirsten
    Lopez Jimenez, Javier
    Kuzmin, Alexej
    Dyer, Martin J. S.
    Le Du, Katell
    Liberati, Anna Marina
    Schlag, Rudolf
    Langerak, Anton W.
    Ritgen, Matthias
    Stilgenbauer, Stephan
    Asikanius, Elina
    Humphrey, Kathryn
    Wenger, Michael K.
    Fingerle-Rowson, Guenter
    Hallek, Michael
    BLOOD, 2014, 124 (21)
  • [44] A phase Ib clinical trial of Ad-ISF35-transduced autologous cells in combination with fludarabine, cyclophosphamide, rituximab (FCR) for patients with fludarabine-refractory and/or del(17p)/p53-defective chronic lymphocytic leukemia (CLL)
    Castro, J. E.
    Schwartzberg, L. S.
    Pinilla-Ibarz, J.
    Kipps, T. J.
    Cantwell, M. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia patients without TP53 disruptions: A real-life CLL campus study
    Visentin, Andrea
    Mauro, Francesca Romana
    Catania, Gioachino
    Fresa, Alberto
    Vitale, Candida
    Sanna, Alessandro
    Mattiello, Veronica
    Cibien, Francesca
    Sportoletti, Paolo
    Gentile, Massimo
    Rigolin, Gian Matteo
    Quaglia, Francesca Maria
    Murru, Roberta
    Gozzetti, Alessandro
    Molica, Stefano
    Marchetti, Monia
    Pravato, Stefano
    Angotzi, Francesco
    Cellini, Alessandro
    Scarfo, Lydia
    Reda, Gianluigi
    Coscia, Marta
    Laurenti, Luca
    Ghia, Paolo
    Foa, Robin
    Cuneo, Antonio
    Trentin, Livio
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [46] Chromosome 8 Abnormalities (8p Losses and 8q Gains) in Patients with Chronic Lymphocytic Leukemia (CLL) and Del(17p)
    Blanco, Gonzalo
    Puiggros, Anna
    Rodriguez-Rivera, Maria
    Melero, Carme
    Dolores Garcia-Malo, Maria
    Collado, Rosa
    Ortega, Margarita
    Jose Calasanz, Mara
    Luno, Elisa
    Teresa Vargas, Maria
    Grau, Javier
    Martinez-Laperche, Carolina
    Valiente, Alberto
    Cervera, Jose
    Pinan, Angeles
    Maria Hernandez-Rivas, Jose
    Batlle, Ana
    Salido, Marta
    Ortuno, Francisco
    Teresa Ardanaz, Ma
    Ferrer, Ana
    Ivars, David
    Rodriguez, Alicia
    Abrisqueta, Pau
    Espinet, Blanca
    BLOOD, 2014, 124 (21)
  • [47] COMPARISON OF CLADRIBINE PLUS CYCLOPHSOPHAMIDE OR FLUDARABINE PLUS CYCLOPHOSPHAMIDE IN DIFFERENT AGE GROUPS IN PREVIOUSLY UNTREATED PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (PALG-CLL3 STUDY)
    Robak, T.
    Blonski, J. Z.
    Gora-Tybor, J.
    Jamroziak, K.
    Konopka, L.
    Ceglarek, B.
    Calbecka, M.
    Kostyra, A.
    Stella-Holowiecka, B.
    Kloczko, J.
    Warzocha, K.
    Seferynska, I.
    Dmoszynska, A.
    Kowal, M.
    Lewandowski, K.
    Dwilewicz-Trojaczek, J.
    Wiater, E.
    Kuliczkowski, K.
    Potoczek, S.
    Hellmann, A.
    Mital, A.
    Skotnicki, A.
    Nowak, W.
    Sulek, K.
    Zdunczyk, A.
    Dybowicz, J.
    Zawilska, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 36 - 36
  • [48] Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL
    Appleby, Niamh
    O'Brien, David
    Quinn, Fiona M.
    Smyth, Liam
    Kelly, Johanna
    Parker, Imelda
    Scott, Kathleen
    Cahill, Mary R.
    Crotty, Gerard
    Enright, Helen
    Hennessy, Brian
    Hodgson, Andrew
    Leahy, Maeve
    O'Leary, Hilary
    O'Dwyer, Michael
    Hayat, Amjad
    Vandenberghe, Elisabeth A.
    LEUKEMIA & LYMPHOMA, 2018, 59 (06) : 1338 - 1347
  • [49] 8q Gains and 8p Losses Are Associated To Even Worse Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) and Del(17p)
    Espinet, Blanca
    Blanco, Gonzalo
    Puiggros, Anna Maria
    Rodriguez-Rivera, Maria
    Garcia-Malo, Ma Dolores
    Ortega, Margarita
    Calasanz, Ma Jose
    Luno, Elisa
    Vargas, Ma Teresa
    Grau, Javier
    Martinez-Laperche, Carolina
    Valiente, Alberto
    Lopez-Pavia, Maria
    Pinan, Ma Angeles
    Hernandez-Rivas, Jesus Ma
    Batlle-Lopez, Ana
    Salido, Marta
    Ardanaz, Maite
    Coado, Rosa
    LABORATORY INVESTIGATION, 2015, 95 : 343A - 343A
  • [50] 8q Gains and 8p Losses Are Associated To Even Worse Outcome in Patients With Chronic Lymphocytic Leukemia (CLL) and Del(17p)
    Espinet, Blanca
    Blanco, Gonzalo
    Maria Puiggros, Anna
    Rodriguez-Rivera, Maria
    Dolores Garcia-Malo, Ma
    Ortega, Margarita
    Jose Calasanz, Ma
    Luno, Elisa
    Teresa Vaigas, Ma
    Grau, Javier
    Martinez-Laperche, Carolina
    Valiente, Alberto
    Lopez-Pavia, Maria
    Angeles Pinan, Ma
    Ma Hernandez-Rivas, Jesus
    Batlle-Lopez, Ana
    Salido, Marta
    Ardanaz, Maite
    Collado, Rosa
    MODERN PATHOLOGY, 2015, 28 : 343A - 343A
12345